Sagility India Limited operates as a healthcare-focused business process management partner serving U.S. payers and providers across claims, clinical, and revenue cycle operations. The business derives 89.6% of its revenue from payers and 10.4% from providers, functioning as a specialized converter of complex healthcare administration into managed outcomes. Operating margins have consistently held in the 24% to 25% adjusted EBITDA range over the last five years, a level of persistence that reveals a high-quality, mission-critical service business rather than a commoditized scale game. The competitive structure is concentrated, with Sagility holding incumbent positions in 7 of the top 10 U.S. payers, while the broader outsourcing penetration remains in the low 20s, leaving a substantial in-house operations market to capture.
The economics of this business persist through a combination of deep domain accumulation and high switching costs evidenced by client tenure. The average tenure of the top five clients is 18 years, with three or four relationships spanning over 20 years, creating an entrenched incumbency advantage that takes years for competitors to replicate. This moat is reinforced by regulatory constraints like HIPAA and clinical judgment requirements that mandate human-in-the-loop AI, preventing fully autonomous competitors from easily displacing the workforce. Sagility further embeds itself by shifting from traditional FTE-based pricing to outcome-based managed service constructs, such as expanding a $6 million scope to a $20 million annual run-rate over a five-year deal, effectively raising the switching costs and making the service integral to client operations.
The 18 to 24 month inflection hinges on the conversion of a $570 million to $575 million total contract value pipeline and the scaling of newly acquired client logos. By the end of FY27, the business is targeted to deliver low double-digit organic constant currency revenue growth, with adjusted EBITDA margins guided between 24% and 25%, likely tracking the upper end if FX remains stable. This trajectory is supported by the Synchrony platform reducing multi-year integration timelines to 9 to 10 months for mid-market payers, alongside the CareSeed acquisition adding 26 new cross-sell targets and BroadPath contributing six to seven active pipeline opportunities. The mix will shift slightly toward onshore delivery, but internal AI deployment is expected to offset this by creating 100 to 200 bps of revenue deflation while lowering the cost of hiring and training.
Management has demonstrated a consistent pattern of under-promising and over-delivering across recent fiscal years. In FY26, they guided for low-to-mid teens organic growth and 23% to 24% EBITDA margins, but delivered 13.8% organic constant currency growth and a 25.3% adjusted EBITDA margin, beating their own upgraded targets. Capital allocation is shifting toward a debt-free structure, with net debt reduced to INR 1,110 million in Q1 FY27 and a commitment to fully repay outstanding debt by the end of FY27. Operating cash flow conversion remained healthy at 104.6% in Q4 FY26, and the board recommended a final dividend of INR 0.10 per share, signaling confidence in underlying cash generation despite elevated IT investments for AI and transformation.
Earnings visibility is anchored by a $130 million cumulative ACV win rate in FY26 converting to revenue, but this path requires successful integration of acquired clients and predictable seasonal open enrollment volumes. The single most important watchpoint is the tension between AI-driven revenue compression and margin expansion. Management expects AI to cause approximately 2% revenue compression in FY27, up from historical 1% to 1.5%, while simultaneously relying on operational efficiencies to absorb a 120 bps headwind from Karnataka and Telangana minimum wage increases. If the Synchrony platform and managed service constructs cannot sufficiently offset onshore mix shifts and wage inflation, the guided 24% to 25% EBITDA margin floor will be the falsifier of the thesis.
companyname: Sagility Limited (formerly Sagility India Limited, earlier Sagility India Private Limited) ticker: SAGILITY sector: Healthcare Business Process Management (BPM) / Healthcare Operations Services Sagility is a technology-enabled healthcare operations company that serves only the U.S. healthcare industry. It runs mission-critical administrative and clinical operations for health insurers (payers), healthcare providers, and pharmacy benefit managers: processing claims, enrolling member...
Read the full report →margin expansion, acquisition inorganic, market share gain, debt reduction
FY27 revenue growth guided at low double-digits in constant currency; adjusted EBITDA margin guided at 24-25%, likely tracking upper end if FX remains stable
Guidance no_dataoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Sagility India Limited and 4,900+ companies.
5-day free pass. No card required.